Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

Allison E Burnett, Charles E Mahan, Sara R Vazquez, Lynn B Oertel, David A Garcia, Jack Ansell, Allison E Burnett, Charles E Mahan, Sara R Vazquez, Lynn B Oertel, David A Garcia, Jack Ansell

Abstract

Venous thromboembolism (VTE) is a serious medical condition associated with significant morbidity and mortality, and an incidence that is expected to double in the next forty years. The advent of direct oral anticoagulants (DOACs) has catalyzed significant changes in the therapeutic landscape of VTE treatment. As such, it is imperative that clinicians become familiar with and appropriately implement new treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance for VTE treatment with the DOACs. When possible, guidance statements are supported by existing published evidence and guidelines. In instances where evidence or guidelines are lacking, guidance statements represent the consensus opinion of all authors of this manuscript and are endorsed by the Board of Directors of the Anticoagulation Forum.The authors of this manuscript first developed a list of pivotal practical questions related to real-world clinical scenarios involving the use of DOACs for VTE treatment. We then performed a PubMed search for topics and key words including, but not limited to, apixaban, antidote, bridging, cancer, care transitions, dabigatran, direct oral anticoagulant, deep vein thrombosis, edoxaban, interactions, measurement, perioperative, pregnancy, pulmonary embolism, reversal, rivaroxaban, switching, \thrombophilia, venous thromboembolism, and warfarin to answer these questions. Non- English publications and publications > 10 years old were excluded. In an effort to provide practical information about the use of DOACs for VTE treatment, answers to each question are provided in the form of guidance statements, with the intent of high utility and applicability for frontline clinicians across a multitude of care settings.

Keywords: Antidotes; Bridging anticoagulation; Care transitions; DOACs; Direct thrombin inhibitors; Drug interactions; Factor Xa inhibitors; NOACs.

Figures

Fig. 1
Fig. 1
Linearity and specificity of coagulation assays for measurement of DOACs [40]. Reproduced with permission from Cuker et al. [40]
Fig. 2
Fig. 2
P-gp effect on drug exposure. Reproduced with permission from Kaatz and Mahan [127]
Fig. 3
Fig. 3
Management of DOAC-associated bleeding

References

    1. Van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320–328. doi: 10.1111/jth.12485.
    1. Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2014
    1. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–718. doi: 10.1056/NEJMoa1113697.
    1. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi: 10.1056/NEJMoa1007903.
    1. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. doi: 10.1056/NEJMoa1207541.
    1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352. doi: 10.1056/NEJMoa0906598.
    1. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–772. doi: 10.1161/CIRCULATIONAHA.113.004450.
    1. EINSTEIN–PE Investigators. Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297. doi: 10.1056/NEJMoa1113572.
    1. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. doi: 10.1056/NEJMoa1302507.
    1. Buller FN, Hokusai-VTE Investigators et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415. doi: 10.1056/NEJMoa1306638.
    1. XARELTO-PM-ENG-10JUL2014-172618.pdf. ? Accessed 11 Nov 2014
    1. Boehringer Ingelheim Canada Ltd (2014) Pradaxa product monograph. . Accessed 11 Nov 2014
    1. Bapat P, Kedar R, Lubetsky A, et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol. 2014;123:1256–1261. doi: 10.1097/AOG.0000000000000277.
    1. Königsbrügge O, Langer M, Hayde M, et al. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost. 2014
    1. Pfizer Canada Inc Eliquis Product Monograph. . Accessed 11 Nov 2014
    1. Savaysa Edoxaban PI. . Accessed 22 Sept 2015
    1. Stangier DJ, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59. doi: 10.2165/00003088-200847010-00005.
    1. Frost CE, Nepal S, Barrett Y, et al. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost. 2009;7(suppl 2):455.
    1. Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908–916. doi: 10.1111/bcp.12114.
    1. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmakokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218–226. doi: 10.1177/0091270006296058.
    1. Schulman S et al (2014) ASH 56th annual meeting San Francisco, CA Dec 2014, session 332 abstract 1544
    1. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014
    1. Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014
    1. Larsen TB, Nielsen PB, Skjoth F, et al. Non-vitamin antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi-systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE. 2014;9:e114445. doi: 10.1371/journal.pone.0114445.
    1. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest. 2014
    1. van der Hulle T, den Exter PL, Kooiman J, et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12:1116–1120. doi: 10.1111/jth.12605.
    1. Sardar P, Chatterjee S, Herzog E, et al. New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther. 2015;22:460–468. doi: 10.1097/MJT.0000000000000055.
    1. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. doi: 10.1056/NEJMoa025313.
    1. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735. doi: 10.1001/archinte.162.15.1729.
    1. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072. doi: 10.1016/j.amjmed.2006.02.022.
    1. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180 day period. Clin Appl Thromb Hemost. 2006;12:389–396. doi: 10.1177/1076029606293692.
    1. Lee A, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686. doi: 10.1001/jama.2015.9243.
    1. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164. doi: 10.1161/CIRCULATIONAHA.114.012061.
    1. Sipahi I, Celik S, Tozun N. A comparison of results of the us food and drug administration’s mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med. 2014;174:150–151. doi: 10.1001/jamainternmed.2013.12217.
    1. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systemic review and meta-analysis. Blood. 2014;124(15):2450–2458. doi: 10.1182/blood-2014-07-590323.
    1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Chest. 2012;141(2 Suppl):e419S–e494S.
    1. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010;9:CD001100.
    1. Funk DM. Coagulation assays and anticoagulant monitoring. Hematology. 2012;2012:460–465.
    1. Tripodi A. The laboratory and the direct oral anticoagulants. Blood. 2013;121:4032–4035. doi: 10.1182/blood-2012-12-453076.
    1. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–1139. doi: 10.1016/j.jacc.2014.05.065.
    1. Douketis J. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: ACCP. Chest. 2012;141:e326S–e350S. doi: 10.1378/chest.11-2298.
    1. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126:343–348. doi: 10.1161/CIRCULATIONAHA.111.090464.
    1. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) Circulation. 2014;129:1850–1859. doi: 10.1161/CIRCULATIONAHA.113.005754.
    1. Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures. Blood. 2014;124(25):3692–3698. doi: 10.1182/blood-2014-08-595496.
    1. Horlocker TT, Wedel DJ, Rowlingson JC et al (2010) Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (3rd Edition). Reg Anesth Pain Med 35(1):64–101 . Accessed 27 Nov 2014
    1. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954–2962. doi: 10.1182/blood-2012-06-415943.
    1. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–2124. doi: 10.1056/NEJMra1206531.
    1. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–2502. doi: 10.1016/j.jacc.2013.02.058.
    1. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24–S33. doi: 10.1016/j.cjca.2013.04.002.
    1. Feinberg J, Grabowitz L, Rotman-Pikielny P, et al. Dabigatran etexilate linked to fatal gastrointestinal hemorrhage. Isr Med Assoc. 2014;16(6):388–389.
    1. Lo JC-Y, Gerona RR. A case of rivaroxaban associated intracranial hemorrhage. West J Emerg Med. 2014;15:375–377. doi: 10.5811/westjem.2014.2.19440.
    1. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. Int J Cardiol. 2013;167:e179–e181. doi: 10.1016/j.ijcard.2013.03.185.
    1. Fountzilas C, George J, Levine R. Dabigatran overdose secondary to acute kidney injury and amiodarone use. N Z Med J. 2013;126:110–112.
    1. Stöllberger C, Finsterer J. Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state. Heart Lung. 2014;43:262–263. doi: 10.1016/j.hrtlng.2014.03.004.
    1. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10:264–271. doi: 10.1016/j.amjopharm.2012.05.002.
    1. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–866. doi: 10.1056/NEJMc1112874.
    1. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: ACCP evidence-based clinical practice guidelines (8th edn) Chest. 2008;133:257S–298S. doi: 10.1378/chest.08-0674.
    1. Hankey GJ, Eikelboom JW. Dabigatran etexilate a new oral thrombin inhibitor. Circulation. 2011;123:1436–1450. doi: 10.1161/CIRCULATIONAHA.110.004424.
    1. Liesenfeld K-H, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168–2175. doi: 10.1111/j.1538-7836.2011.04498.x.
    1. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–2789. doi: 10.1093/eurheartj/ehr113.
    1. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. doi: 10.1056/NEJMoa1112277.
    1. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708. doi: 10.1056/NEJMoa1105819.
    1. Davidson BL, Verheijen S, Lensing AA, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014;174:947–953. doi: 10.1001/jamainternmed.2014.946.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638.
    1. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039.
    1. Abo-Salem E, Becker R. Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. J Thromb Thrombolysis. 2014;37:372–379. doi: 10.1007/s11239-014-1060-y.
    1. Atay JK, Fanikos J, Barnes GD, et al. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol. 2013;112:387–389. doi: 10.1016/j.amjcard.2013.03.046.
    1. Pottegård A, Poulsen BK, Larsen MD, Hallas J. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost. 2014;12:1413–1418. doi: 10.1111/jth.12662.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi: 10.1056/NEJMoa1310907.
    1. Majeed A, Hwang H-G, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–2332. doi: 10.1161/CIRCULATIONAHA.113.002332.
    1. Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873–1880. doi: 10.1093/eurheartj/ehu083.
    1. Hylek E, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial: predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141–2147. doi: 10.1016/j.jacc.2014.02.549.
    1. Research C for DE and drug safety and availability—FDA Drug Safety Communication: FDA study of medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. . Accessed 27 Nov 2014
    1. Siegal DM, Cuker A. Reversal of target-specific oral anticoagulants. Drug Discov Today. 2014
    1. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood. 2011;118(21):1004.
    1. Van Ryn J, et al. 13th congress of the European Hematology Association, Copenhagen, Denmark, June 12–15, 2008. Haematologica. 2008;93(s-1):148.
    1. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemostas. 2012;10(9):1841–1848. doi: 10.1111/j.1538-7836.2012.04859.x.
    1. Martin AC, LeBonniec B, Fischer AM. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. J Int Card. 2013;168(4):4228–4233. doi: 10.1016/j.ijcard.2013.07.152.
    1. Perzborn E, Gruber A, Tinel H, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013;110(1):162–172. doi: 10.1160/TH12-12-0907.
    1. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131:82–90. doi: 10.1161/CIRCULATIONAHA.114.013445.
    1. Godier A, Miclot A, LeBonniec B, Durand M, Fischer A-M, Emmerich J, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116(1):94–102. doi: 10.1097/ALN.0b013e318238c036.
    1. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217–247. doi: 10.1160/TH12-03-0179.
    1. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;1214:1573–1579. doi: 10.1161/CIRCULATIONAHA.111.029017.
    1. Dager WE, Gosselin RC, Roberts AJ, et al. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013;41(5):42–46. doi: 10.1097/CCM.0b013e31827caaa3.
    1. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost. 2011;106:429–438. doi: 10.1160/TH11-01-0052.
    1. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791–1800. doi: 10.1056/NEJMoa1006221.
    1. Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant–associated bleeding. Blood. 2014;123:1152–1158. doi: 10.1182/blood-2013-09-529784.
    1. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141–S145. doi: 10.1002/ajh.23202.
    1. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis. 2013;36:195–202. doi: 10.1007/s11239-013-0923-y.
    1. van Ryn J et al (2014) American Heart Association Scientific Sessions 2014, Chicago, USA.
    1. Glund S (2013) 17765—A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Paper presented at the American Heart Association Scientific Sessions, Dallas, Texas, 16–20 November 2013
    1. NCT02104947
    1. Hutchchaleelaha A, et al. European society of cardiology annual meeting. Germany: Munich; 2012.
    1. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–451. doi: 10.1038/nm.3102.
    1. Crowther M; ASH 2014 San Francisco abstract #4269 Session 332. antithrombotic therapy: poster III Monday, December 8
    1. Crowther M, et al; ASH 2013. Abstract 3636, session 332. antithrombotic therapy: poster III Monday, December 9, 2013
    1. Crowther M, et al. ISTH 2013 Amsterdam
    1. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban—full text view—. . Accessed 27 Nov 2014
    1. A study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of apixaban—full text view—. . Accessed 27 Nov 2014
    1. Laulicht B, Bakhru S, Jiang X, et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June 29–July 4, 2013. Abstract (
    1. Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med. 2014;371:2141–2142. doi: 10.1056/NEJMc1411800.
    1. Pollack CV, Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–520. doi: 10.1056/NEJMoa1502000.
    1. Crowther MA, et al (2015) ISTH Congress 2015 abstract LB004
    1. Burton R (2012) Improving care transitions. Robert Wood Johnson Foundation Health Policy Brief Sept 13, 2012.
    1. Schillig J, Kaatz S, Hudson M, et al. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6:322–328. doi: 10.1002/jhm.910.
    1. Makowski CT, Jennings DL, Nemerovski CW, et al. The impact of pharmacist-directed patient education and anticoagulant care coordination on patient satisfaction. Ann Pharmacother. 2013;47:805–810. doi: 10.1345/aph.1R686.
    1. Spyropoulos AC, Viscusi A, Singhal N, et al. Features of electronic health records necessary for the delivery of optimized anticoagulant therapy consensus of the EHR Task Force of the New York State Anticoagulation Coalition. Ann Pharmacother. 2014
    1. Cowell RPW. Direct oral anticoagulants: integration into clinical practice. Postgrad Med J. 2014;90:529–539. doi: 10.1136/postgradmedj-2013-132474.
    1. Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013;6:215–228. doi: 10.2147/JMDH.S44068.
    1. Spyropoulos AC, Kardos J, Wigal P. Outcome analyses of the outpatient treatment of venous thromboemolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm. 2000;6:298–304.
    1. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383–1389. doi: 10.1001/archinternmed.2010.199.
    1. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–651. doi: 10.1093/europace/eut083.
    1. James, J (2013) patient engagement. In: Health affairs. . Accessed 27 Nov 2014
    1. Hibbard JH, Greene J, Overton V. Patients with lower activation associated with higher costs; delivery systems should know their patients’ “Scores”. Health Aff. 2013;32:216–222. doi: 10.1377/hlthaff.2012.1064.
    1. Johnson A, Sandford J, Tyndall J. Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst Rev. 2003
    1. Institute for Safe Medication Practices (ISMP) (2003) . Accessed 27 Nov 2014
    1. Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G, et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11(1):177–179. doi: 10.1111/jth.12038.
    1. Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program. 2013;2013:464–470. doi: 10.1182/asheducation-2013.1.464.
    1. Cushman M. Treating acute venous thromboembolism—shift with Care. N Engl J Med. 2013;369(9):865–866. doi: 10.1056/NEJMe1307413.
    1. Thachil J. The newer direct oral anticoagulants: a practical guide. Clin Med. 2014;14:165–175. doi: 10.7861/clinmedicine.14-2-165.
    1. Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematology. 2012;2012:536–540.
    1. Schulman S. New oral anticoagulant agents—general features and outcomes in subsets of patients. Thromb Haemost. 2014;111(4):575–582. doi: 10.1160/TH13-09-0803.
    1. Mahan CE, Spyropoulos AC, Fisher MD, et al. Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. Clin Appl Thromb Hemost. 2013;19:504–512. doi: 10.1177/1076029612470967.
    1. Decousus H, Tapson VF, Bergmann J-F, et al. Factors at admission associated with bleeding risk in medical patients: findings from the improve investigators. Chest. 2011;139:69–79. doi: 10.1378/chest.09-3081.
    1. IPRO MAPP tool.
    1. Kaatz S, Mahan CE. Stroke prevention in patients with atrial fibrillation and renal dysfunction. Stroke. 2014;45:2497–2505. doi: 10.1161/STROKEAHA.114.005117.
    1. Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring. Semin Thromb Hemost. 2014;40:756–765. doi: 10.1055/s-0034-1381233.
    1. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448–458. doi: 10.1124/dmd.109.029694.
    1. Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74:490–500. doi: 10.1111/j.1365-2125.2012.04218.x.
    1. Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, et al. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos. 2014;42:257–263. doi: 10.1124/dmd.113.053769.
    1. Mendell J, Zahir H, Matsushima N, et al. Drug–drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13:331–342. doi: 10.1007/s40256-013-0029-0.
    1. Delavenne X, Ollier E, Basset T, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol. 2013;76(1):107–113. doi: 10.1111/bcp.12055.
    1. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. 2012. WA: Freeland; 2012.
    1. FDA document: drug interactions and labeling > drug development and drug interactions: table of substrates, inhibitors, and inducers.
    1. Risselada AJ, Visser MJ, van Roon EN. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157:A6568.
    1. Altena R, van Roon E, Folkeringa R, et al. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica. 2014;99:e26–e27. doi: 10.3324/haematol.2013.097287.
    1. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455–466. doi: 10.1111/bcp.12075.
    1. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372–380. doi: 10.1124/jpet.111.180240.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera